Dr. Antonio Milici of GeneThera, Inc. Nominated for National Advisory Committee on Meat & Poultry

WHEAT RIDGE, CO--(Marketwire - January 30, 2009) - GeneThera, Inc. (PINKSHEETS: GTHR) announced today its President & CEO, Dr. Antonio Milici, has been nominated for the National Advisory Committee on Meat & Poultry.

The Committee is part of the USDA’s food inspection service. Nominations for membership are sought from individuals representing industry, academia, State and local government officials, public health organizations, and consumers and consumer organizations. The full committee consists of 16 to 18 members, and each person is expected to serve a two-year term.

The NACMPI was established in 1971 to the provide advice and recommendations to the U.S. Secretary of Agriculture on meat and poultry inspection programs. Membership is drawn from a broad range of groups interested in food safety including consumers, producers, processors, exporters and importers of meat and poultry products, as well as those in academia, public health, and federal and state government.

GeneThera is exceptionally honored to have its founder and President nominated for this position.

Dr. Milici had this comment on his nomination: “If I am appointed to this committee, I will use my position to better protect the American public from food borne pathogens of all types. GeneThera is committed to the safety and security of the food that goes on the plates of all Americans. For too long, we have had to wonder if the food we are buying from the grocery stores or restaurants and feeding to our children is truly safe. With the increased use of antibiotics and supplements in cattle, we have seen the rise of harmful and often deadly pathogens such as E.Coli. There was a time that we felt safe eating a rare hamburger, or eating lettuce without even washing it. Now, the American people must be cautious with every bit of food or drink we put into our bodies. Today we are in the midst of the largest outbreak of salmonella in our history. Too often the victims of these outbreaks are the extremely young or elderly; those of our nation that are the weakest. It is time we stand up and take the actions necessary to protect them. The technology to eliminate many of these pathogens does exist, we just need some support to bring it to the forefront.”

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GES™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne’s disease. For more information, contact Dr. Tony Milici MD, PHD at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends,” “believes,” and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.